The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: venous thromboembolism following therapy with an immune checkpoint inhibitor
Parameters:
(1) type of thromboembolism
(2) complications
(3) intervention required
|
Type of Thrombosis
|
Complications
|
Intervention Required
|
Grade
|
|
superficial thrombosis
|
uncomplicated
|
symptomatic
|
G1
|
|
deep vein thrombosis
|
uncomplicated
|
medical
|
G2
|
|
thrombosis with pulmonary embolism
|
uncomplicated
|
urgent
|
G3
|
|
NA
|
life-threatening; organ damage; amputation
|
emergency
|
G4
|
Other causes of hypercoagulability should be excluded, although a patient with cancer often will have multiple risk factors for thrombosis.
